57 results about "Haemophilus influenzae type" patented technology

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus influenzae type b and tetanus toxoid or diphtheria toxoid, which may be reconstituted from a lyophilized state by the other component. The administration of the multiple component vaccine resulted in no diminution of the immunogenicity of any component as a result of interference by other components of the vaccine.

The invention provides a multivalent immunogenic composition containing enterovirus antigens. The composition comprises inactivated EV71 antigens and/or inactivated CA16 antigens, and inactivated polio antigens. The composition can further comprise antigens selected from hepatitis A antigens, hepatitis B antigens, acellular pertussis antigens, tetanus toxoid, diphtheria toxoid, Haemophilus influenzae type b capsular polysaccharide, and meningococcal polysaccharide antigens, as well as physiologically acceptable carriers combined with bacterial polysaccharide antigens. The invention also provides a preparation method of the composition. The composition can prevent invasion of a plurality of pathogens simultaneously without interference among the antigens, and the immunogenicity is no less than that of individually activated antigens. With the composition, vaccination processes are significantly simplified, and the vaccination efficiency is improved with reduced costs.

The invention discloses a method for rapid purification of bacterial capsular polysaccharide. The method can fast remove pollutants comprising proteins and nucleic acid from a specific bacterial fermentation broth and retains purified capsular polysaccharide. The method comprises the following steps of fermentation of capsular polysaccharide-containing bacteria, acid adjustment of a pH value of a fermentation broth, precipitation of thalli and impurities of the fermentation broth, centrifugation, microfiltration, ultrafiltration condensation and filter wash so that a crude bacterial capsular polysaccharide solution is obtained. A basic principle of the method comprises that through acid adjustment, a pH value of a fermentation broth is in a range of 3 to 5 so that thalli having whole shapes and other impurities are removed and capsular polysaccharide is retained in the fermentation broth and thus purification of capsular polysaccharide is realized. The method can be used for purification of capsular polysaccharide of pneumococcocci, haemophilus influenzae type b, epidemic meningococcocci and typhoid bacillus.

The present invention relates to immunogenic compositions comprising one or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae.

The invention discloses a haemophilus influenzae type b (Hib) polysaccharide and refined tetanus toxoid coupling process which includes steps of Hib polysaccharide-AH derivant generation and Hib polysaccharide-tetanus toxoid (TT) combination preparation. The Hib polysaccharide-AH derivant generation includes steps of A1, polysaccharide dissolving, A2, polysaccharide activation, A3, antidiuretic hormone addition for connection and A4, CNBr and antidiuretic hormone (ADH) removing. The Hib polysaccharide-TT combination preparation includes the following steps: B1, adding TT solution, B2, adding carbodiimide (EDAC), B3, removing the EDAC to obtain polysaccharide-TT carbodiimide; and B4, separating and pourifying the polysaccharide-TT carbodiimide, eluting, degerming and filtering to obtain the polysaccharide-TT combination. The Hib polysaccharide and refined tetanus toxoid coupling process has the advantages of improving working efficiency, saving time and labor and simultaneously saving using amount of NaCl solution and reduces the contaminated rate of samples compared with dialysis adopted by the traditional process.

The invention discloses a high-density culture and production method of bacterium capsular polysaccharide with haemophilus influenzae type b. The method comprises following steps: subculturing Hib strains from a first generation to a fourth generation, carrying out culture in a seeding tank, carrying out fermentation and culture in a fermentation tank, killing bacteria, acquiring a supernatant, and purifying the supernatant. Beneficial effects of the invention are as follows: (1) by culturing Hib bacteria to a high concentration, output of Hib capsular polysaccharide is improved by 50% to 100% on the basis of the output of Hib capsular polysaccharide produced by the traditional way, and produced capsular polysaccharide meets the national standard; (2) by controlling nucleic acids, protein, and other impurities in a zymotic fluid to a low level, the number of times of phenol extracting for removing impurity protein is reduced for relatively low protein content, thereby reducing phenol amount used in subsequent purifying processes, reducing environmental pollution, and reducing production cost; and (3) output of polysaccharide is stable, and content of refined glycoprotein, endotoxin, and other impurities after the purifying is substantially lower than the national control standard.

The invention discloses a process for activating a Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccine, which comprises the following steps of: A, preparing Hib polysaccharide; B, dissolving 1-Cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) by using acetonitrile into a solution; C, preparing the Hib polysaccharide into a solution; D, adding the CDAP solution to the Hib polysaccharide solution, and stirring for 2-5 minutes at the room temperature; E, dissolving adipic dihydrazide (ADH) by using NaHCO3 into a solution, adding the ADH solution to a mixed solution, and stirring for 0.5-2 hours at the room temperature; and F, collecting eluent of the void volume from a loading solution after the reaction is ended at a SephadexG-25 gel chromatography column balanced in advance by water for injection, and performing freeze drying to obtain a Hib polysaccharide-ADH derivative. The process for activating the Hib polysaccharide conjugate vaccine has the beneficial effects that the quality index of the prepared Hib polysaccharide-ADH can reach the industrial standard, and moreover, the safe and nontoxic CDAP is adopted to serve as an activating agent instead of cyanogen bromide which is greatly harmful to human and environment, and therefore, the safety is enhanced, and the harm to the human and the environment are avoided.

The invention discloses a dyeing method for bacterial capsules in Haemophilus influenzae type b fermentation broth. The method comprises the steps of pretreatment, smear preparation, smearing, drying, dyeing, secondary drying and microscopic examination The method employs the principle of negative dyeing, which guarantees that bacterial capsules are integral and thalluses occupy a great area and are easy to identify; a good dyeing effect is obtained, and color contrast between the capsules and a background is obvious, so the capsules can be easily observed; operation process is simple and does not have high requirements on operating skill of a tester, so the success rate of testing is high.

The invention discloses a preparing method of group A and group C meningococcus and haemophilus influenzae type b combined vaccine. The method includes the steps of preparing a monovalent vaccine stock solution, preparing the combined vaccine and freeze-drying the vaccine. The invention provides the preparing method of the group A and group C meningococcus and haemophilus influenzae type b combined vaccine, group A and group C meningococcus and haemophilus influenzae type b are combined together, and the prepared combined vaccine is remarkable in effect; as the vaccine is of combined type, the number of times of inoculation is reduced, infant trauma is reduced, the inoculation cost is reduced, and the combined vaccine has good social and economic benefits. The method is easy to operate and suitable for large-scale industrial production, and the combined vaccine is easy to prepare and low in cost.

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide of Haemophilus influenzae type b and tetanus toxoid or diphteria toxoid, which may be reconstituted from a lyophilized state by the other components of the vaccine. The administration of the multiple component vaccine results in no diminution in the immunogenicity of any component as a result of interference by other components of the vaccine.

The invention provides a HIB (Haemophilus influenzae type B) synthetic medium, a HIB conjugate vaccine and a preparation method of the HIB conjugate vaccine, relates to the field of a vaccine production preparation technology and solves the problems that the HIB conjugate vaccine contains haematogenous components, is likely to have an anaphylactic reaction, is unstable and high in cost and has high content of nucleic acid, egg white and endotoxin. The HIB synthetic medium comprises following components in terms of final concentration: 5-15 g/l of yeast extract powder, 5-15 g/l of glucose, 1-3 g/l of MgCl2*6H2O, 0.01-0.03 g/l of beta-coenzyme, 0.005-0.02 g/l of hemin, 22-32 g/l of Na2HPO4*12H2O and 2-5 g/l of NaH2PO4*2H2O. The medium does not contain the haematogenous components and macromolecular allergen components, so that strain passage is more stable, safer and more reliable, and the prepared HIB conjugate vaccine has low endotoxin content and good stability and is safe and effective.

The invention provides a polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine. Each dose of the combined vaccine contains 50-500 micrograms/ml and 10-60 micrograms/ml of B-type haemophilus influenzae capsule polysaccharide, and the serotype of pneumococcus is one or more of 1A, 3A, 4A, 5A, 6A, 6B, 7F, 8N, 9N, 9V, 12F, 14B, 15B, 18C, 19A, 19F, 22F and 23F. Compared with the prior art, the combined vaccine is safe, reliable and good in stability, and the application prospect of the combined vaccine is very wide.

A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.